|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) |
1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
First Eagle Value in Biotechnology Master Fund, Ltd. C/O FIRST EAGLE INVESTMENT MGMNT LLC 1345 AVENUE OF THE AMERICAS NEW YORK, NY 10105 |
X | |||
First Eagle Investment Management, LLC 1345 AVENUE OF THE AMERICAS NEW YORK, NY 10105 |
X |
First Eagle Value in Biotechnology Master Fund, Ltd.(+) By: /s/ Daniel DuClue | 12/11/2009 | |
**Signature of Reporting Person | Date | |
First Eagle Investment Management, LLC(+), By: /s/ Daniel DeClue | 12/11/2009 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | These securities may be deemed to be indirectly beneficially owned by FIRST EAGLE INVESTMENT MANAGEMENT, LLC ("FEIM") as investment adviser to FIRST EAGLE VALUE IN BIOTECHNOLOGY MASTER FUND, LTD. ("FEVIBMF", and together with FEIM, the "Reporting Persons"). |
(2) | These securities may be deemed to be indirectly beneficially owned by FEIM as investment adviser to accounts other than FEVIBMF. |
(3) | The acquisition listed herein was effected by in-kind transactions between FEVIBMF and other accounts managed by FEIM. |
(4) | The disposition listed herein was effected by in-kind transactions between FEVIBMF and other accounts managed by FEIM. |
Remarks: (+) The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended or for any other purpose. |